arrow
M

Manel Mendoza

Universitat Autonoma de Barcelona
H指数:19
被引数:1,322

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Unlocking insights: Validating a comprehensive model for predicting spontaneous preterm delivery and microbial invasion in women facing preterm labor

解锁见解:验证用于预测面临早产孕妇的自发性早产和微生物入侵的综合性模型

2026-09-300
OAAI
Prediction of preterm pre-eclampsia and preterm small-for-gestational-age at 24–28 weeks of gestation using ultrasound and biochemical markers in high-risk pregnancies treated with aspirin: A secondary analysis of the StopPRE trial

使用超声和生物化学标志物预测接受阿司匹林治疗的高危妊娠在24~28周时的早产子痫前期和早产胎儿宫内生长受限:StopPRE试验的二次分析

2026-09-300
PRE
Protocol for a prospective observational cohort study to assess clinical applications of expanded noninvasive prenatal testing (NIPT) in pregnancies with placental dysfunction

前瞻性观察队列研究方案:评估在胎盘功能障碍妊娠中扩展型无创产前检测(NIPT)的临床应用

2026-04-090
OA
Angiogenic factors and fetal Doppler for predicting adverse pregnancy outcome in early-onset small fetuses with and without pre-eclampsia

血管生成因子和胎儿多普勒在预测伴有或不伴有子痫前期早期发病的小胎儿不良妊娠结局中的应用

2026-02-220
OAAI
Clinical practice guidance for the management of fetal growth restriction: an expert review

Villalain, C.; Herraiz, I.; Akolekar, R.; Figueras, F.; Crispi, F.; Rizzo, G.; Mappa, I.; Mendoza, M.; Del Moral, T.; Stampalija, T.; et al. 胎儿生长受限的管理临床实践指南:一项专家综述。J. Matern. Fetal Neonatal Med. 2025, 38, 2526111. [Google Scholar] [CrossRef]

2025-12-312
PRE
Aspirin Discontinuation at 24-28 Weeks and Placental Biomarker Trajectories: Post Hoc Analysis of a Randomised Trial

阿司匹林在24-28周停药与胎盘生物标志物轨迹:一项随机试验的事后分析

2025-09-010
PRE
Role of routine uterine artery Doppler at 18-22 and 24-28 weeks' gestation following routine first-trimester screening for pre-eclampsia

常规妊娠早期筛查先兆子痫后,在妊娠18-22和24-28周时常规子宫动脉多普勒的作用

2024-12-050
PRE
Placental growth factor at 24-28 weeks for aspirin discontinuation in pregnancies at high risk for preterm preeclampsia: Post hoc analysis of StopPRE trial
2024-08-222
OAAI
Clinical effectiveness of routine first-trimester combined screening for pre-eclampsia in Spain with the addition of placental growth factor
2023-10-092
OA